The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

Thu, 29th Jun 2023 18:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

----------

Serica Energy PLC - London-based oil & gas company focused on the UK North Sea - Provides update at annual general meeting. Says net production for the combined Serica and Tailwind portfolios has averaged over 49,000 barrels of oil equivalent per day in the year to June 24. Full year 2023 production guidance remains unchanged at 40,000-47,000 boe/d. Production costs for the group are running at around USD17/boe year-to-date in line with expectations.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Updates on the progress made on business development and partnering activities relating to XF-73 Nasal, its lead asset. Says active discussions are progressing at various stages with a number of interested global parties having access to the XF-73 data room, and the company anticipates several more potential partners will be granted access in the coming months. Further, says search for permanent chief executive officer continues.

----------

Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Completes subscription, retail offer and placing to raise total GBP380,477, announced on June 27. Further, places extra 2 million shares to raise GBP345,000. Proceeds to be used for further expansion and diversification of its client base, expansion of its consulting business and exploration of opportunities around its personalised oncology software offering.

----------

Ceres Power Holdings PLC - clean energy technology developer - Shares cancelled for trading on AIM on Thursday and admitted to listing on the premium listing segment of the Official List.

----------

Faron Pharmaceuticals Oy - Finland-based clinical-stage biopharmaceutical company - Conducts private placement to a limited number of institutional and other investors to raise EUR 6.6 million. Significant majority of the net proceeds will be used for the acceleration of the bexmarilimab clinical development program and manufacturing. Explains proceeds of the placing, together with other currently confirmed funding, are expected to provide the company with working capital into the fourth quarter of 2023.

----------

Jadestone Energy PLC - oil and gas production company focused on Asia-Pacific region - Reports acceptances of only 0.5% of eligible shareholders for open offer announced earlier in June. Notes the company's share price was below the open offer price of 45 pence per share for the duration of the open offer, which is likely to explain the level of applications. Open offer will thus raise USD33,101.

----------

Ecofin US Renewables Infrastructure Trust - London-based investor in US renewable energy assets - Expects net cash flows at the portfolio level to be meaningfully lower than forecast for the quarters ending June 30 and September 30, with overall cash flows currently expected to return to forecast levels by the end of the calendar year. Says this reduction comes as a result of certain operational issues, including the recent events at Whirlwind, corrective maintenance interruptions at some of the solar assets leading to lower-than-expected energy performance, and one-time costs. As a result, expects to declare a reduced dividend of not less than 0.70 US cents per share in respect of the quarter ending June 30. Believes a temporary reduction at this time is prudent. It had paid a first-quarter dividend of 1.4 US cents per share.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Nov 2018 13:09

Destiny Pharma Biofilm Project With Southampton Uni Secures Funding

LONDON (Alliance News) - Destiny Pharma PLC said Thursday it had been jointly granted funding with the University of Southampton to examine the use of its technology to eradicate clinical caused a

Read more
25 Oct 2018 11:23

Destiny Pharma Hires Creabilis's Shaun Claydon As New Finance Head

LONDON (Alliance News) - Destiny Pharma PLC said on Thursday it has appointed Shaun Claydon as its new finance chief after the departure of Chief Financial Officer Simon Sacerdoti.Claydon,

Read more
19 Oct 2018 14:54

Destiny Pharma helps with new bioindustry association videos

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.

Read more
26 Sep 2018 12:39

Destiny Pharma Loss More Than Doubles On Administrative Expenses

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday reported a substantial widening of its loss in the first half of the year due to administrative expenses.The clinical stage company

Read more
6 Sep 2018 13:24

Destiny Pharma Chairman Nigel Rudd To Step Down In December

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that Chairman Nigel Rudd stepped down from the company in December after eight years.Non-Executive Director Nick Rodgers will Rudd

Read more
6 Sep 2018 10:32

Chairman of Destiny calling time after 15 years with pharma firm

(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.

Read more
26 Jul 2018 13:49

Destiny Pharma Receives Positive Results From Skin Irritation Study

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that it received positive data from the Phase I of its XF-73 skin irritation study.The clinical stage biotechnology company said is

Read more
21 Jun 2018 10:25

Destiny Pharma Appoints SEHTA Chairman Nick Rodgers As Non-Executive

LONDON (Alliance News) - Anti-microbial resistance-focused biotechnology developer Destiny Pharma PLC said Thursday it has appointed Nick Rodgers as an independent non-executive director with is a

Read more
30 May 2018 13:00

Destiny Pharma Creates Independent Scientific Advisory Board

LONDON (Alliance News) - Destiny Pharma PLC said Wednesday it has formed a scientific advisory board to provide "expert, independent analysis" of the company's research and clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.